Abstract
We compared adherence to and acceptability of daily topical and oral formulations of tenofovir (TFV) used as pre-exposure prophylaxis (PrEP) for HIV prevention among women in South Africa, Uganda and the United States. 144 sexually active, HIV-uninfected women participated in a cross-over study of three regimens: oral tablet, vaginal gel, or both. We tested for differences in adherence and evaluated product acceptability. Self-reported adherence for all regimens was high (94 %), but serum TFV concentrations indicated only 64 % of participants used tablets consistently. Most women in the U.S. (72 %) favored tablets over gel; while preferences varied at the African sites (42 % preferred gel and 40 % tablets). Findings indicate a role for oral and vaginal PrEP formulations and highlight the importance of integrating pharmacokinetics-based adherence assessment in future trials. Biomedical HIV prevention interventions should consider geographic and cultural experience with product formulations, partner involvement, and sexual health benefits that ultimately influence use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 737-747 |
| Number of pages | 11 |
| Journal | AIDS and Behavior |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2013 |
Fingerprint
Keywords
- Administration
- Anti-infective agents
- Foams and jellies
- HIV
- Microbicide
- Oral
- Patient compliance
- PrEP
- Sexual behavior
- Vaginal creams
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases
- Social Psychology
Cite this
Adherence and acceptability in MTN 001 : A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. / Minnis, Alexandra M.; Gandham, Sharavi; Richardson, Barbra A.; Guddera, Vijayanand; Chen, Beatrice A.; Salata, Robert; Nakabiito, Clemensia; Hoesley, Craig; Justman, Jessica; Soto-Torres, Lydia; Patterson, Karen; Gomez, Kailazarid; Hendrix, Craig.
In: AIDS and Behavior, Vol. 17, No. 2, 02.2013, p. 737-747.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adherence and acceptability in MTN 001
T2 - A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women
AU - Minnis, Alexandra M.
AU - Gandham, Sharavi
AU - Richardson, Barbra A.
AU - Guddera, Vijayanand
AU - Chen, Beatrice A.
AU - Salata, Robert
AU - Nakabiito, Clemensia
AU - Hoesley, Craig
AU - Justman, Jessica
AU - Soto-Torres, Lydia
AU - Patterson, Karen
AU - Gomez, Kailazarid
AU - Hendrix, Craig
PY - 2013/2
Y1 - 2013/2
N2 - We compared adherence to and acceptability of daily topical and oral formulations of tenofovir (TFV) used as pre-exposure prophylaxis (PrEP) for HIV prevention among women in South Africa, Uganda and the United States. 144 sexually active, HIV-uninfected women participated in a cross-over study of three regimens: oral tablet, vaginal gel, or both. We tested for differences in adherence and evaluated product acceptability. Self-reported adherence for all regimens was high (94 %), but serum TFV concentrations indicated only 64 % of participants used tablets consistently. Most women in the U.S. (72 %) favored tablets over gel; while preferences varied at the African sites (42 % preferred gel and 40 % tablets). Findings indicate a role for oral and vaginal PrEP formulations and highlight the importance of integrating pharmacokinetics-based adherence assessment in future trials. Biomedical HIV prevention interventions should consider geographic and cultural experience with product formulations, partner involvement, and sexual health benefits that ultimately influence use.
AB - We compared adherence to and acceptability of daily topical and oral formulations of tenofovir (TFV) used as pre-exposure prophylaxis (PrEP) for HIV prevention among women in South Africa, Uganda and the United States. 144 sexually active, HIV-uninfected women participated in a cross-over study of three regimens: oral tablet, vaginal gel, or both. We tested for differences in adherence and evaluated product acceptability. Self-reported adherence for all regimens was high (94 %), but serum TFV concentrations indicated only 64 % of participants used tablets consistently. Most women in the U.S. (72 %) favored tablets over gel; while preferences varied at the African sites (42 % preferred gel and 40 % tablets). Findings indicate a role for oral and vaginal PrEP formulations and highlight the importance of integrating pharmacokinetics-based adherence assessment in future trials. Biomedical HIV prevention interventions should consider geographic and cultural experience with product formulations, partner involvement, and sexual health benefits that ultimately influence use.
KW - Administration
KW - Anti-infective agents
KW - Foams and jellies
KW - HIV
KW - Microbicide
KW - Oral
KW - Patient compliance
KW - PrEP
KW - Sexual behavior
KW - Vaginal creams
UR - http://www.scopus.com/inward/record.url?scp=84880192830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880192830&partnerID=8YFLogxK
U2 - 10.1007/s10461-012-0333-8
DO - 10.1007/s10461-012-0333-8
M3 - Article
C2 - 23065145
AN - SCOPUS:84880192830
VL - 17
SP - 737
EP - 747
JO - AIDS and Behavior
JF - AIDS and Behavior
SN - 1090-7165
IS - 2
ER -